Gilead's Phase 1 Data Shows Promise For Once-Yearly Lenacapavir In HIV Prevention

RTTNews) - Gilead Sciences Inc. (GILD) announced that phase 1 study data showed two different formulations of once-yearly lenacapavir, administered via intramuscular injection, achieved and maintained plasma concentrations exceeding those associated with HIV prevention efficacy...

Market Touch Signal is a free discovery window from Oy Market Touch Ltd. Practical intelligence, clear communication and useful digital ventures: https://market-touch.org/
Get In Touch

Market Touch Signal · Finland · international digital desk

+358 400 512311

info@market-touch.org

Follow Us
Flickr Photos
© 2026 Oy Market Touch Ltd. · Market Touch Signal